There have been few recent studies describing the incidence and causes of hypophosphataemia in a hospital population and the frequency of concomitant hypokalaemia, In this study a majority (53070) of patients with hypophosphataemia had been on a glucose infusion at the time of their low plasma phosphate. The largest patient group found to show hypophosphataemia « O·8 mmol/L) were in the Intensive Therapy Unit (lTU), and this was also the largest patient group manifesting severe hypophosphataemia «0·3 mmol/L). Approximately, 11% of patients with hypophosphataemia ( < O·8 mmol/L) had a plasma potassium equal to or less than 3' 5 mmol/L, compared with 5· 7% of hospital patients without hypophosphataemia.
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Furthermore, 20% of patients with severe hypophosphataemia ( < o· 3 mmol/L) had hypokalaemia as similarly defined.
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Phosphate is an essential anion important in many bodily functions, for example, phosphate has a role in the nucleotide status of cells, I it can act as a physiological buffer, it is involved in bone mineralization and is an effector of certain enzymes, including phosphofructokinase and hexokinase.? Furthermore, increased phosphate concentrations stimulate the synthesis of 2,3 diphosphoglycerate (2,3 DPG), which is involved in oxygen transport by haernoglobin.? Phosphate is predominantly an intracellular ion, there being an intracellular to extracellular molar ratio of phosphate of about 80:3.
Hypophosphataernia can present clinically in an insidious way as myalgia, weakness, anorexia and malaise. In severe hypophosphataemia rhabdomyolysis, haemolysis, platelet and leucocyte dysfunction may occur, as might seizures, coma and respiratory failure."
In this study the incidence and causes of hypophosphataernia in a hospital population were examined, with special emphasis on severe hypophosphataernia. In addition, the association between hypophosphataemia and hypokalaemia was also examined.
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METHODS
The study was divided into two parts. In the first part all the plasma phosphate results in a I year period were searched using the laboratory computer (Ferranti-Delphi Phoenix System). These results were then sub-divided into those results lower than O:50 mmol/L, a value requiring appropriate therapy' and those results equal to or less than O:30 mmol/L, the value below which serious clinical sequelae may result." The records of all the patients with a plasma phosphate of equal to or less than O·30 mmol/L (over the I year study period), were examined to ascertain the patients' clinical condition and plasma potassium status.
The second part of the study involved a review of the records of 100 patients with a plasma phosphate of equal to or below O·80 mmol/L. This study was designed so as to be able to attribute clinical causes for the hypophosphataemia in this group. One hundred patients was felt to be a sufficient number to allow a reasonably unbiased selection of patients over the period studied and yet at the same time be a number that would not be too cumbersome for adequate exploration of the records. 
RESULTS
Plasma phosphate was measured on a Hitachi 737 analyser, using the assay based on phosphomolybdate formation at 340 nm. Plasma potassium was measured by indirect ion selective electrodes on the same analyser. Plasma was analysed as soon as possible after reception in the laboratory. The between batch coefficient of variation (CV) for phosphate was 4· 80/0 and for potassium 2'5%. Calibration was achieved using calibrators supplied by Boehringer Mannheim (UK) Ltd for Hitachi auto-analysers.
Because this study was retrospective there was very little control over the time of venesection for blood sampling. However, over 850/0 of the samples were probably taken within 4 h of a hospital meal, during the post absorptive phase when phosphate concentrations might be expected to be lower than at time of fasting.
During the I year period 119 369 total requests were received, of which 51988 (44%) included plasma phosphate. The distribution of plasma phosphate in these patients is shown in Table 1 . Of these patients 13% had mild (0'51-0'80 mmollL), 1% had moderate (0' 31-0' 50 mmollL) and O' 04070 had severe ( < O· 30 mmollL) hypophosphataernia. Of the 100patients with hypophosphataemia, in whom records were examined, 53070 had been on intravenous fluid therapy including either 5070 dextrose or dextrose-saline ( 
DISCUSSION
It is well known that glucose administration promotes a shift of phosphate into the cell/,8 and so it was anticipated that hypophosphataernia would occur in patients receiving intravenous dextrose infusion. However, it was of interest to find that more than half of the cases of hypophosphataernia could be attributed to this therapy and that this percentage rose with the severity of the hypophosphataemia. It is also probable that a significant number of cases of mild hypophosphataemia can be attributed to sampling during the post-absorptive phase where a similar mechanism will obtain.
It is worthy of note that 22% of our hypophosphataemic patients were in ITU where the effects of mechanical ventilation on the distribution of the anion'v? must be contributory factors in addition to glucose therapy. Similarly, altered renal tubular function resulting from the use of chemotherapeutic agents such as cisplatinum will contribute to the hypophosphataemia of malignancy and the use of tn-adrenergic agonists will contribute to the hypophosphataemia of obstructive airways disease. The aetiology of hypophosphataemia following myocardial infarction remains unknown." All other causes of hypophosphataemia listed in Tables 2 and 3 have been reported previouslyY- 18 This study confirms the association between hypophosphataemia and bypokalaemia.P-" The most likely common link is intravenous dextrose therapy which affects phosphate and potassium in the same way by movement of the ions into cells. However, tn-adrenergic agonists can cause hypokalaemia and in severe potassium deficiency damage to the renal tubule may cause phosphate leakage.P
The recognition and correction of severe hypophosphataemia will improve the well being of hospital patients," and this is especially relevant for patients in lTU since reversing hypophosphataemia may improve respiratory muscle weakness.F Financial pressures may cause some laboratories to reassess the value of phosphate measurement. Whilst it may be difficult to justify the measurement of the anion in all routine electrolyte screens, physicians should be encouraged to request phosphate measurement in patients receiving intravenous glucose, in patients in ITU and in patients with malignancy as well as the more standard requests in patients with chronic renal failure or metabolic bone disease. It is advisable to measure fasting plasma phosphate concentrations to confirm the diagnosis of hypophosphataemia in patients with no obvious cause. Potassium status should be monitored closely in patients with severe hypophosphataemia.
